Viking Therapeutics’ dual-formulation obesity drug could be the David to Lilly’s Goliath.
Is Eli Lilly Stock a Buy? Here’s What the Market Isn’t Pricing in Yet.
August 16, 2025
You may also like
Indices by TradingView
Tech’s Data-Center Capex Isn’t Creating Jobs. That Matters for Stocks.
September 9, 2025
OpenAI Helps Google Win in Court
September 8, 2025
Nvidia Shares Climb Despite Citi Trims Target on Broadcom AI Threat
September 8, 2025
Categories
Indices by TradingView